The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma
Abstract
Purpose: Medulloblastoma is the most common malignant brain tumor in children. Despite multimodal aggressive treatment, nearly half of the patients die as a result of this tumor. Identification of molecular markers for prognosis and development of novel pathogenesis-based therapies depends crucially on a better understanding of medulloblastoma pathomechanisms. Patients and Methods: We performed genome-wide analysis of DNA copy number imbalances in 47 medulloblastomas using comparative genomic hybridization to large insert DNA microarrays (matrix-CGH). The expression of selected candidate genes identified by matrix-CGH was analyzed immunohistochemically on tissue microarrays representing medulloblastomas from 189 clinically well-documented patients. To identify novel prognostic markers, genomic findings and protein expression data were correlated to patient survival. Results: Matrix-CGH analysis revealed frequent DNA copy number alterations of several novel candidate regions. Among these, gains at 17q23.2-qter (P < .01) and losses at 17p13.1 to 17p13.3 (P = .04) were significantly correlated to poor prognosis. Within 17q23.2-qter and 7q21.2, two of the most frequently gained chromosomal regions, confined amplicons were identified that contained the PPM1D and CDK6 genes, respectively. Immunohistochemistry revealed strong expression of PPM1D in 148 (88%) of 168 and CDK6 in 50 (30%) of 169 medulloblastomas. Overexpression of CDK6 correlated significantly with poor prognosis (P < .01) and represented an independent prognostic marker of overall survival on multivariate analysis (P = .02). Conclusion: We identified CDK6 as a novel molecular marker that can be determined by immunohistochemistry on routinely processed tissue specimens and may facilitate the prognostic assessment of medulloblastoma patients. Furthermore, increased protein-levels of PPM1D and CDK6 may link the TP53 and RB1 tumor suppressor pathways to medulloblastoma pathomechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
REN KCTD11 is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma
Di Marcotullio, L., Ferretti, E., De Smaele, E., Argenti, B., Mincione, C., Zazzeroni, F., Gallo, R., Masuelli, L., Napolitano, M., Maroder, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400690101 · Cited by 179
Cited by
Medulloblastomics: the end of the beginning
Northcott, P. A., Jones, D. T. W., Kool, M., Robinson, G. W., Gilbertson, R. J., Cho, Y.-J., Pomeroy, S. L., Korshunov, A., Lichter, P., Taylor, M. D., et al. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3410 · Cited by 663
Self-citationMicroRNA-34a Inhibits Glioblastoma Growth by Targeting Multiple Oncogenes
Li, Y., Guessous, F., Zhang, Y., DiPierro, C., Kefas, B., Johnson, E., Marcinkiewicz, L., Jiang, J., Yang, Y., Schmittgen, T. D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0529 · Cited by 614
Fellermann, K., Stange, D. E., Schaeffeler, E., Schmalzl, H., Wehkamp, J., Bevins, C. L., Reinisch, W., Teml, A., Schwab, M., Lichter, P., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/505915 · Cited by 565
Self-citationBRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas
Pfister, S., Janzarik, W. G., Remke, M., Ernst, A., Werft, W., Becker, N., Toedt, G., Wittmann, A., Kratz, C., Olbrich, H., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33656 · Cited by 523
Self-citationCyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.035 · Cited by 393
Metadata
- Authors
- Mendrzyk, F., Radlwimmer, B., Joos, S., Kokocinski, F., Benner, A., Stange, D. E., Neben, K., Fiegler, H., Carter, N. P., Reifenberger, G., Korshunov, A., & Lichter, P.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-12-01
- Volume
- 23
- Issue
- 34
- Pages
- 8853-8862
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2135595576
- Cited by
- 213
- References
- 2
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma. https://app.cochat.ai/papers/10.1200/jco.2005.02.8589
- The paper
- Mendrzyk, F., Radlwimmer, B., Joos, S., Kokocinski, F., Benner, A., Stange, D. E., Neben, K., Fiegler, H., Carter, N. P., Reifenberger, G., Korshunov, A., & Lichter, P. (2005). Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.02.8589
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.